- Home
- TNXP vs IAE Comparison
TNXP vs IAE Comparison
Compare TNXP & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- IAE
- Stock Information
- Founded
- TNXP 2007
- IAE 2007
- Country
- TNXP United States
- IAE United States
- Employees
- TNXP N/A
- IAE N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- IAE Trusts Except Educational Religious and Charitable
- Sector
- TNXP Health Care
- IAE Finance
- Exchange
- TNXP Nasdaq
- IAE Nasdaq
- Market Cap
- TNXP 71.6M
- IAE 69.8M
- IPO Year
- TNXP N/A
- IAE N/A
- Fundamental
- Price
- TNXP $18.18
- IAE $6.17
- Analyst Decision
- TNXP Strong Buy
- IAE
- Analyst Count
- TNXP 2
- IAE 0
- Target Price
- TNXP $585.00
- IAE N/A
- AVG Volume (30 Days)
- TNXP 2.6M
- IAE 46.3K
- Earning Date
- TNXP 03-18-2025
- IAE 01-01-0001
- Dividend Yield
- TNXP N/A
- IAE 10.21%
- EPS Growth
- TNXP N/A
- IAE N/A
- EPS
- TNXP N/A
- IAE N/A
- Revenue
- TNXP $10,094,000.00
- IAE N/A
- Revenue This Year
- TNXP $84.08
- IAE N/A
- Revenue Next Year
- TNXP $126.94
- IAE N/A
- P/E Ratio
- TNXP N/A
- IAE N/A
- Revenue Growth
- TNXP 29.94
- IAE N/A
- 52 Week Low
- TNXP $6.76
- IAE $5.31
- 52 Week High
- TNXP $672.00
- IAE $6.45
- Technical
- Relative Strength Index (RSI)
- TNXP 48.95
- IAE 46.59
- Support Level
- TNXP $12.80
- IAE $6.20
- Resistance Level
- TNXP $31.87
- IAE $6.26
- Average True Range (ATR)
- TNXP 4.30
- IAE 0.07
- MACD
- TNXP 0.57
- IAE 0.00
- Stochastic Oscillator
- TNXP 22.53
- IAE 43.48
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.